CD8A and neoplasm: This B16 immunotherapeutic induced CD8+ and CD4+ T-cell responses in naïve mice from different parts of the fusion protein, including the N-terminal first (Pmel) and C-terminal last segment (PADRE). Consistently, our surrogate immunotherapeutic exhibited anti-tumoural efficacy in B16.F10 tumour-bearing mice, thus supporting the functionality of CVGBM mRNA and protein design.